论文部分内容阅读
目的观察急性冠状动脉综合征(ACS)早期盐酸替罗非班治疗对血清C-反应蛋白(C-re-active protein,CRP)水平的影响,了解盐酸替罗非班对ACS斑块稳定性和免疫炎症抑制的作用。方法 63例初次确诊为ACS患者分为常规治疗组29例和盐酸替罗非班治疗组34例,测定63例ACS患者治疗前后血清CRP水平。结果盐酸替罗非班治疗组34例ACS患者治疗后血清C-反应蛋白水平明显下降,与常规治疗组比较有显著统计学差异(P<0.01)。结论 ACS患者早期予以盐酸替罗非班治疗,可明显降低血清炎症因子水平,从而改善该病进程。
Objective To investigate the effects of early ticrofibacil treatment on the level of C-reactive protein (CRP) in patients with acute coronary syndrome (ACS) and to investigate the effects of tirofiban on the stability of ACS plaque and The role of immune inflammation suppression. Methods Totally 63 ACS patients were divided into routine treatment group (n = 29) and tirofiban hydrochloride treatment group (n = 34). 63 cases of ACS patients were measured before and after treatment of serum CRP levels. Results Serum C-reactive protein level was significantly decreased in 34 patients with ACS treated with tirofiban hydrochloride, which was significantly different from the conventional treatment group (P <0.01). Conclusions ACS patients treated with tirofiban hydrochloride early can significantly reduce serum levels of inflammatory cytokines and thus improve the course of the disease.